Sarepta Therapeutics
SRPT
#4359
Rank
NZ$4.13 B
Marketcap
NZ$39.42
Share price
-4.00%
Change (1 day)
-69.30%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

Revenue for Sarepta Therapeutics (SRPT)

Revenue in 2024: NZ$3.37 Billion

According to Sarepta Therapeutics 's latest financial reports the company's current revenue (TTM ) is NZ$4.16 Billion. In 2024 the company made a revenue of NZ$3.37 Billion an increase over the revenue in the year 2023 that were of NZ$1.96 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Sarepta Therapeutics from 1997 to 2024

Annual revenue

Year Revenue Change
2024NZ$3.37 B71.53%
2023NZ$1.96 B33.79%
2022NZ$1.46 B43.01%
2021NZ$1.02 B37.28%
2020NZ$0.74 B32.37%
2019NZ$0.56 B26%
2018NZ$0.44 B106.19%
2017NZ$0.21 B2681.26%
2016NZ$7.82 M327.47%
2015NZ$1.83 M-85.3%
2014NZ$12.45 M-28.03%
2013NZ$17.3 M-61.87%
2012NZ$45.37 M-24.63%
2011NZ$60.2 M57.88%
2010NZ$38.13 M57.48%
2009NZ$24.21 M-33.89%
2008NZ$36.63 M155.44%
2007NZ$14.34 M8663.35%
2006NZ$0.16 M-97.66%
2005NZ$6.99 M1060.17%
2004NZ$0.6 M-59.57%
2003NZ$1.49 M-6.69%
2002NZ$1.59 M-5.97%
2001NZ$1.7 M-41.92%
2000NZ$2.92 M664.96%
1999NZ$0.38 M-49.58%
1998NZ$0.75 M46.82%
1997NZ$0.51 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Gilead Sciences
GILD
NZ$50.85 B 1,119.74%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
NZ$2.98 B-28.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
NZ$1.76 B-57.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
NZ$6.41 B 53.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Insmed
INSM
NZ$1.04 B-74.88%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
NZ$1.51 B-63.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNAM
NZ$32.39 M-99.22%๐Ÿ‡บ๐Ÿ‡ธ USA